These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 32900500)

  • 1. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Wallbillich JJ; Morris RT; Ali-Fehmi R
    Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline mutations of the DNA repair pathways in uterine serous carcinoma.
    Frimer M; Levano KS; Rodriguez-Gabin A; Wang Y; Goldberg GL; Horwitz SB; Hou JY
    Gynecol Oncol; 2016 Apr; 141(1):101-7. PubMed ID: 27016235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
    D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
    Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
    Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
    Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
    [No Abstract]   [Full Text] [Related]  

  • 6. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA germline mutations in women with uterine serous carcinoma--still a debate.
    Lavie O; Ben-Arie A; Segev Y; Faro J; Barak F; Haya N; Auslender R; Gemer O
    Int J Gynecol Cancer; 2010 Dec; 20(9):1531-4. PubMed ID: 21119368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma.
    Bruchim I; Amichay K; Kidron D; Attias Z; Biron-Shental T; Drucker L; Friedman E; Werner H; Fishman A
    Int J Gynecol Cancer; 2010 Oct; 20(7):1148-53. PubMed ID: 21206239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report.
    Pepe F; Pisapia P; Russo G; Nacchio M; Pallante P; Vigliar E; De Angelis C; Insabato L; Bellevicine C; De Placido S; Troncone G; Malapelle U
    Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
    Choi MC; Hwang S; Kim S; Jung SG; Park H; Joo WD; Song SH; Lee C; Kim TH; Kang H; An HJ
    Cancer Res Treat; 2020 Apr; 52(2):634-644. PubMed ID: 32019284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.
    Mittempergher L; Piskorz AM; Bosma AJ; Michaut M; Wisman GBA; Kluin RJC; Nieuwland M; Brugman W; van der Ven KJW; Marass F; Morris J; Rosenfeld N; Jimenez-Linan M; de Jong S; van der Zee AGJ; Brenton JD; Bernards R
    PLoS One; 2020; 15(7):e0235766. PubMed ID: 32639993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.
    de Jonge MM; Mooyaart AL; Vreeswijk MP; de Kroon CD; van Wezel T; van Asperen CJ; Smit VT; Dekkers OM; Bosse T
    Eur J Cancer; 2017 Feb; 72():215-225. PubMed ID: 28049106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the differences in oncologic outcomes between patients with high-grade serous ovarian carcinoma and uterine serous carcinoma.
    Kilic F; Ersak B; Cakir C; Yuksel D; Kilic C; Korkmaz V; Tokgozoglu N; Toptas T; Boran N; Kimyon Comert G; Ureyen I; Tasci T; Moraloglu Tekin O; Ustun Y; Turan T
    J Obstet Gynaecol Res; 2024 Jan; 50(1):86-94. PubMed ID: 37854000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.